Whats new
Whats new.
CLSA Equity Research - PD-L1 competition good for efti - GSK’s PD-L1 result highlights increasing competition for Keytruda (ASX:IMM) (Analyst: Andrew Paine)
October 6th 2022
For a copy of this analyst report please contact your CLSA advisor